{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:58:49Z","timestamp":1789595929383,"version":"build-2803163510"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"18","license":[{"start":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T00:00:00Z","timestamp":1606521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T00:00:00Z","timestamp":1606521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004755","name":"EMD Serono, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40265-020-01422-9","type":"journal-article","created":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T14:02:21Z","timestamp":1606572141000},"page":"1901-1928","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review"],"prefix":"10.1007","volume":"80","author":[{"given":"Kottil","family":"Rammohan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia K.","family":"Coyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Sylvester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Galazka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Dangond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Grosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Leist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,28]]},"reference":[{"issue":"11","key":"1422_CR1","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1212\/WNL.0000000000000768","volume":"83","author":"P Browne","year":"2014","unstructured":"Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, et al. Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology. 2014;83(11):1022\u20134. https:\/\/doi.org\/10.1212\/WNL.0000000000000768.","journal-title":"Neurology"},{"issue":"3","key":"1422_CR2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S1474-4422(18)30443-5","volume":"18","author":"GBD 2016 Multiple Sclerosis Collaborators","year":"2019","unstructured":"GBD 2016 Multiple Sclerosis Collaborators. Global, regional, and national burden of multiple sclerosis 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(3):269\u201385. https:\/\/doi.org\/10.1016\/S1474-4422(18)30443-5.","journal-title":"Lancet Neurol"},{"key":"1422_CR3","unstructured":"Wallin MT, Culpepper WJ, Campbell J, Nelson LM, Langer-Gould A, Marrie RA et al. The prevalence of multiple sclerosis in the United States: a population-based healthcare database approach. Paris, France: European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 25\u201328 October 2017. p 344."},{"key":"1422_CR4","unstructured":"National Multiple Sclerosis Society. Relapsing-remitting MS. https:\/\/www.nationalmssociety.org\/What-is-MS\/Types-of-MS\/Relapsing-remitting-MS. Accessed 24 Jul 2020."},{"issue":"2","key":"1422_CR5","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s11136-005-0891-6","volume":"15","author":"A Miller","year":"2006","unstructured":"Miller A, Dishon S. Health-related quality of life in multiple sclerosis: the impact of disability, gender and employment status. Qual Life Res. 2006;15(2):259\u201371. https:\/\/doi.org\/10.1007\/s11136-005-0891-6.","journal-title":"Qual Life Res"},{"issue":"6 Suppl","key":"1422_CR6","first-page":"s151","volume":"22","author":"GM Owens","year":"2016","unstructured":"Owens GM. Economic burden of multiple sclerosis and the role of managed care organizations in multiple sclerosis management. Am J Manag Care. 2016;22(6 Suppl):s151\u2013s158158.","journal-title":"Am J Manag Care"},{"issue":"81","key":"1422_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20810","volume":"20","author":"K Tilling","year":"2016","unstructured":"Tilling K, Lawton M, Robertson N, Tremlett H, Zhu F, Harding K, et al. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort. Health Technol Assess. 2016;20(81):1\u201348. https:\/\/doi.org\/10.3310\/hta20810.","journal-title":"Health Technol Assess"},{"issue":"2","key":"1422_CR8","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1136\/practneurol-2018-002060","volume":"19","author":"R Dobson","year":"2019","unstructured":"Dobson R, Dassan P, Roberts M, Giovannoni G, Nelson-Piercy C, Brex PA. UK consensus on pregnancy in multiple sclerosis: 'Association of British Neurologists' guidelines. Pract Neurol. 2019;19(2):106\u201314. https:\/\/doi.org\/10.1136\/practneurol-2018-002060.","journal-title":"Pract Neurol"},{"issue":"12","key":"1422_CR9","doi-asserted-by":"publisher","first-page":"e0227120","DOI":"10.1371\/journal.pone.0227120","volume":"14","author":"S Burkill","year":"2019","unstructured":"Burkill S, Vattulainen P, Geissbuehler Y, Sabido Espin M, Popescu C, Suzart-Woischnik K, et al. The association between exposure to interferon-beta during pregnancy and birth measurements in offspring of women with multiple sclerosis. PLoS One. 2019;14(12):e0227120. https:\/\/doi.org\/10.1371\/journal.pone.0227120.","journal-title":"PLoS One"},{"key":"1422_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09762-y","author":"K Hellwig","year":"2020","unstructured":"Hellwig K, Geissbuehler Y, Sabido M, Popescu C, Adamo A, Klinger J, et al. Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry. J Neurol. 2020. https:\/\/doi.org\/10.1007\/s00415-020-09762-y.","journal-title":"J Neurol"},{"key":"1422_CR11","unstructured":"European Medicines Agency. Rebif - Procedural steps taken and scientific information after the authorisation. Amsterdam, The Netherlands. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/procedural-steps-after\/rebif-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf. Accessed 11 Feb 2020."},{"key":"1422_CR12","unstructured":"Mavenclad [summary of product characteristics]. Amsterdam: Merck Europe B.V.; 2020."},{"issue":"1","key":"1422_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.7224\/1537-2073.2016-079","volume":"20","author":"M Sandberg-Wollheim","year":"2018","unstructured":"Sandberg-Wollheim M, Neudorfer O, Grinspan A, Weinstock-Guttman B, Haas J, Izquierdo G, et al. Pregnancy outcomes from the branded glatiramer acetate pregnancy database. Int J MS Care. 2018;20(1):9\u201314. https:\/\/doi.org\/10.7224\/1537-2073.2016-079.","journal-title":"Int J MS Care"},{"issue":"6","key":"1422_CR14","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1177\/1352458515623366","volume":"22","author":"S Herbstritt","year":"2016","unstructured":"Herbstritt S, Langer-Gould A, Rockhoff M, Haghikia A, Queisser-Wahrendorf A, Gold R, et al. Glatiramer acetate during early pregnancy: a prospective cohort study. Mult Scler. 2016;22(6):810\u20136. https:\/\/doi.org\/10.1177\/1352458515623366.","journal-title":"Mult Scler"},{"key":"1422_CR15","unstructured":"Copaxone [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; 2016."},{"key":"1422_CR16","unstructured":"Plegridy [package insert]. Cambridge, MA: Biogen Inc.; 2014."},{"key":"1422_CR17","unstructured":"Rebif [package insert]. Rockland, MA: EMD Serono, Inc.; 2015."},{"key":"1422_CR18","unstructured":"Avonex [package insert]. Cambridge, MA: Biogen Inc.; 2016."},{"key":"1422_CR19","unstructured":"Betaseron [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals; 2018."},{"key":"1422_CR20","unstructured":"Aubagio [package insert]. Cambridge, MA: Genzyme Corporation; 2016."},{"key":"1422_CR21","unstructured":"Gilenya [package insert]. Stein, Switzerland: Novartis Phama Stein AG; 2019."},{"key":"1422_CR22","unstructured":"Tecfidera [package insert]. Cambridge, MA: Biogen Inc.; 2017."},{"key":"1422_CR23","unstructured":"Tysabri [package insert]. Cambridge, MA: Biogen Inc.; 2018."},{"key":"1422_CR24","unstructured":"Lemtrada [package insert]. Cambridge, MA: Genzyme Corporation; 2019."},{"key":"1422_CR25","unstructured":"Ocrevus [package insert]. San Francisco, CA: Genentech, Inc.; 2018."},{"key":"1422_CR26","unstructured":"Mavenclad [package insert]. Rockland, MA: EMD Serono, Inc.; 2019."},{"issue":"8","key":"1422_CR27","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1136\/jnnp-2016-315238","volume":"88","author":"HMB Lunde","year":"2017","unstructured":"Lunde HMB, Assmus J, Myhr KM, Bo L, Grytten N. Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study. J Neurol Neurosurg Psychiatry. 2017;88(8):621\u20135. https:\/\/doi.org\/10.1136\/jnnp-2016-315238.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"1422_CR28","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1212\/WNL.0b013e3181cf6ec0","volume":"74","author":"RA Marrie","year":"2010","unstructured":"Marrie RA, Yu N, Blanchard J, Leung S, Elliott L. The rising prevalence and changing age distribution of multiple sclerosis in Manitoba. Neurology. 2010;74(6):465\u201371. https:\/\/doi.org\/10.1212\/WNL.0b013e3181cf6ec0.","journal-title":"Neurology"},{"issue":"7","key":"1422_CR29","doi-asserted-by":"publisher","first-page":"e005718","DOI":"10.1136\/bmjopen-2014-005718","volume":"4","author":"M Ploughman","year":"2014","unstructured":"Ploughman M, Beaulieu S, Harris C, Hogan S, Manning OJ, Alderdice PW, et al. The Canadian survey of health, lifestyle and ageing with multiple sclerosis: methodology and initial results. BMJ Open. 2014;4(7):e005718. https:\/\/doi.org\/10.1136\/bmjopen-2014-005718.","journal-title":"BMJ Open"},{"key":"1422_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ebiom.2017.01.042","volume":"16","author":"D Baker","year":"2017","unstructured":"Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K. Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis. EBioMedicine. 2017;16:41\u201350. https:\/\/doi.org\/10.1016\/j.ebiom.2017.01.042.","journal-title":"EBioMedicine"},{"issue":"1","key":"1422_CR31","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/WNF.0b013e318204cd90","volume":"34","author":"T Leist","year":"2011","unstructured":"Leist T, Weissert R. Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol. 2011;34(1):28\u201335. https:\/\/doi.org\/10.1097\/WNF.0b013e318204cd90.","journal-title":"Clin Neuropharmacol"},{"issue":"9","key":"1422_CR32","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nri3871","volume":"15","author":"CA Dendrou","year":"2015","unstructured":"Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015;15(9):545\u201358. https:\/\/doi.org\/10.1038\/nri3871.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"1422_CR33","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0165-6147(03)00028-2","volume":"24","author":"O Neuhaus","year":"2003","unstructured":"Neuhaus O, Archelos JJ, Hartung HP. Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection. Trends Pharmacol Sci. 2003;24(3):131\u20138. https:\/\/doi.org\/10.1016\/S0165-6147(03)00028-2.","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"1422_CR34","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cell.2018.08.011","volume":"175","author":"I Jelcic","year":"2018","unstructured":"Jelcic I, Al Nimer F, Wang J, Lentsch V, Planas R, Jelcic I, et al. Memory B cells activate brain-homing, autoreactive CD4(+) T cells in multiple sclerosis. Cell. 2018;175(1):85\u2013100. https:\/\/doi.org\/10.1016\/j.cell.2018.08.011(e23).","journal-title":"Cell"},{"key":"1422_CR35","unstructured":"Betaferon [package insert]. Berlin, Germany: Bayer AG; 2018."},{"issue":"2","key":"1422_CR36","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1212\/WNL.58.2.169","volume":"58","author":"DS Goodin","year":"2002","unstructured":"Goodin DS, Frohman EM, Garmany GP Jr, Halper J, Likosky WH, Lublin FD, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58(2):169\u201378.","journal-title":"Neurology"},{"key":"1422_CR37","unstructured":"CenterWatch. Tysabri (natalizumab). https:\/\/www.centerwatch.com\/drug-information\/fda-approved-drugs\/drug\/869\/tysabri-natalizumab. Accessed 22 Jul 2019."},{"issue":"6","key":"1422_CR38","doi-asserted-by":"publisher","first-page":"670","DOI":"10.4161\/mabs.2.6.13270","volume":"2","author":"P Fontoura","year":"2010","unstructured":"Fontoura P. Monoclonal antibody therapy in multiple sclerosis: paradigm shifts and emerging challenges. MAbs. 2010;2(6):670\u201381. https:\/\/doi.org\/10.4161\/mabs.2.6.13270.","journal-title":"MAbs"},{"issue":"2","key":"1422_CR39","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1212\/CPJ.0000000000000227","volume":"6","author":"T Spelman","year":"2016","unstructured":"Spelman T, Kalincik T, Jokubaitis V, Zhang A, Pellegrini F, Wiendl H, et al. Comparative efficacy of first-line natalizumab vs IFN-beta or glatiramer acetate in relapsing MS. Neurol Clin Pract. 2016;6(2):102\u201315. https:\/\/doi.org\/10.1212\/CPJ.0000000000000227.","journal-title":"Neurol Clin Pract"},{"issue":"9","key":"1422_CR40","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/1756285617716002","volume":"10","author":"BA Singer","year":"2017","unstructured":"Singer BA. The role of natalizumab in the treatment of multiple sclerosis: benefits and risks. Ther Adv Neurol Disord. 2017;10(9):327\u201336. https:\/\/doi.org\/10.1177\/1756285617716002.","journal-title":"Ther Adv Neurol Disord"},{"key":"1422_CR41","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.msard.2017.10.002","volume":"18","author":"T Eagle","year":"2017","unstructured":"Eagle T, Stuart F, Chua AS, LaRussa A, Leclaire K, Cook SL, et al. Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis. Mult Scler Relat Disord. 2017;18:196\u2013201. https:\/\/doi.org\/10.1016\/j.msard.2017.10.002.","journal-title":"Mult Scler Relat Disord"},{"key":"1422_CR42","unstructured":"Ocrevus [summary of product characteristics]. Grenzach-Wyhlen: Roche Pharma AG; 2018."},{"key":"1422_CR43","unstructured":"Lemtrada [summary of product characteristics]. Haverhill: Genzyme Ltd.; 2018."},{"key":"1422_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/cells8010012","author":"S Gingele","year":"2018","unstructured":"Gingele S, Jacobus TL, Konen FF, Hummert MW, Suhs KW, Schwenkenbecher P, et al. Ocrelizumab depletes CD20(+) T cells in multiple sclerosis patients. Cells. 2018. https:\/\/doi.org\/10.3390\/cells8010012.","journal-title":"Cells"},{"issue":"1","key":"1422_CR45","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1177\/1756285615601933","volume":"9","author":"PS Sorensen","year":"2016","unstructured":"Sorensen PS, Blinkenberg M. The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects. Ther Adv Neurol Disord. 2016;9(1):44\u201352. https:\/\/doi.org\/10.1177\/1756285615601933.","journal-title":"Ther Adv Neurol Disord"},{"key":"1422_CR46","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2147\/JIR.S38079","volume":"7","author":"O Fernandez","year":"2014","unstructured":"Fernandez O. Alemtuzumab in the treatment of multiple sclerosis. J Inflamm Res. 2014;7:19\u201327. https:\/\/doi.org\/10.2147\/JIR.S38079.","journal-title":"J Inflamm Res"},{"issue":"5","key":"1422_CR47","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s00415-018-8830-y","volume":"265","author":"B Ceronie","year":"2018","unstructured":"Ceronie B, Jacobs BM, Baker D, Dubuisson N, Mao Z, Ammoscato F, et al. Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells. J Neurol. 2018;265(5):1199\u2013209. https:\/\/doi.org\/10.1007\/s00415-018-8830-y.","journal-title":"J Neurol"},{"issue":"10","key":"1422_CR48","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrneurol.2017.119","volume":"13","author":"H Wiendl","year":"2017","unstructured":"Wiendl H. Cladribine\u2014an old newcomer for pulsed immune reconstitution in MS. Nat Rev Neurol. 2017;13(10):573\u20134. https:\/\/doi.org\/10.1038\/nrneurol.2017.119.","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"1422_CR49","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1007\/s12026-018-9032-5","volume":"66","author":"D Karussis","year":"2018","unstructured":"Karussis D, Petrou P. Immune reconstitution therapy (IRT) in multiple sclerosis: the rationale. Immunol Res. 2018;66(6):642\u20138. https:\/\/doi.org\/10.1007\/s12026-018-9032-5.","journal-title":"Immunol Res"},{"key":"1422_CR50","unstructured":"European Medicines Agency. Mavenclad - summary of EPAR. 2017. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mavenclad. Accessed 29 Jan 2019."},{"key":"1422_CR51","unstructured":"FDA approves new oral treatment for multiple sclerosis [press release]. US Food and Drug Administration; 29 March 2019. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-oral-treatment-multiple-sclerosis. Accessed 11 Feb 2020."},{"issue":"9","key":"1422_CR52","doi-asserted-by":"publisher","first-page":"784","DOI":"10.7326\/0003-4819-120-9-199405010-00010","volume":"120","author":"A Saven","year":"1994","unstructured":"Saven A, Piro LD. 2-Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies. Ann Intern Med. 1994;120(9):784\u201391.","journal-title":"Ann Intern Med"},{"issue":"8914","key":"1422_CR53","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(94)91046-4","volume":"344","author":"JC Sipe","year":"1994","unstructured":"Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet. 1994;344(8914):9\u201313.","journal-title":"Lancet"},{"issue":"4","key":"1422_CR54","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1182\/blood.V62.4.737.737","volume":"62","author":"DA Carson","year":"1983","unstructured":"Carson DA, Wasson DB, Taetle R, Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood. 1983;62(4):737\u201343.","journal-title":"Blood"},{"issue":"6","key":"1422_CR55","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1586\/14737175.5.6.721","volume":"5","author":"JC Sipe","year":"2005","unstructured":"Sipe JC. Cladribine for multiple sclerosis: review and current status. Expert Rev Neurother. 2005;5(6):721\u20137. https:\/\/doi.org\/10.1586\/14737175.5.6.721.","journal-title":"Expert Rev Neurother"},{"issue":"8825","key":"1422_CR56","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/0140-6736(92)92826-2","volume":"340","author":"E Beutler","year":"1992","unstructured":"Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet. 1992;340(8825):952\u20136. https:\/\/doi.org\/10.1016\/0140-6736(92)92826-2.","journal-title":"Lancet"},{"issue":"12","key":"1422_CR57","doi-asserted-by":"publisher","first-page":"5677","DOI":"10.1073\/pnas.74.12.5677","volume":"74","author":"DA Carson","year":"1977","unstructured":"Carson DA, Kaye J, Seegmiller JE. Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s). Proc Natl Acad Sci USA. 1977;74(12):5677\u201381.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"1422_CR58","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1007\/s13311-017-0573-4","volume":"14","author":"G Giovannoni","year":"2017","unstructured":"Giovannoni G. Cladribine to treat relapsing forms of multiple sclerosis. Neurotherapeutics. 2017;14(4):874\u201387. https:\/\/doi.org\/10.1007\/s13311-017-0573-4.","journal-title":"Neurotherapeutics"},{"issue":"11","key":"1422_CR59","doi-asserted-by":"publisher","first-page":"6865","DOI":"10.1073\/pnas.77.11.6865","volume":"77","author":"DA Carson","year":"1980","unstructured":"Carson DA, Wasson DB, Kaye J, Ullman B, Martin DW Jr, Robins RK, et al. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci USA. 1980;77(11):6865\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1422_CR60","unstructured":"National Center for Biotechnology Information. PubChem Database. Cladribine, CID=20279. National Institutes of Health. 2019. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Cladribine. Accessed 19 Jun 2019."},{"issue":"12","key":"1422_CR61","doi-asserted-by":"publisher","first-page":"5551","DOI":"10.1073\/pnas.0913900107","volume":"107","author":"G Toy","year":"2010","unstructured":"Toy G, Austin WR, Liao HI, Cheng D, Singh A, Campbell DO, et al. Requirement for deoxycytidine kinase in T and B lymphocyte development. Proc Natl Acad Sci USA. 2010;107(12):5551\u20136. https:\/\/doi.org\/10.1073\/pnas.0913900107.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"1422_CR62","doi-asserted-by":"publisher","first-page":"5551","DOI":"10.1073\/pnas.0913900107","volume":"107","author":"G Toy","year":"2010","unstructured":"Toy G, Austin WR, Liao HI, Cheng D, Singh A, Campbell DO, et al. Requirement for deoxycytidine kinase in T and B lymphocyte development [supplement]. Proc Natl Acad Sci USA. 2010;107(12):5551\u20136. https:\/\/doi.org\/10.1073\/pnas.0913900107.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"16","key":"1422_CR63","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1182\/blood-2010-02-246140","volume":"116","author":"DS Sigal","year":"2010","unstructured":"Sigal DS, Miller HJ, Schram ED, Saven A. Beyond hairy cell: the activity of cladribine in other hematologic malignancies. Blood. 2010;116(16):2884\u2013966. https:\/\/doi.org\/10.1182\/blood-2010-02-246140.","journal-title":"Blood"},{"key":"1422_CR64","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.msard.2019.01.038","volume":"29","author":"G Comi","year":"2019","unstructured":"Comi G, Cook S, Giovannoni G, Rieckmann P, Sorensen PS, Vermersch P, et al. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Mult Scler Relat Disord. 2019;29:168\u201374. https:\/\/doi.org\/10.1016\/j.msard.2019.01.038.","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"1422_CR65","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","volume":"362","author":"G Giovannoni","year":"2010","unstructured":"Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sorensen P, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416\u201326. https:\/\/doi.org\/10.1056\/NEJMoa0902533.","journal-title":"N Engl J Med"},{"issue":"12","key":"1422_CR66","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1177\/1352458517727603","volume":"24","author":"G Giovannoni","year":"2018","unstructured":"Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult Scler. 2018;24(12):1594\u2013604. https:\/\/doi.org\/10.1177\/1352458517727603.","journal-title":"Mult Scler"},{"key":"1422_CR67","doi-asserted-by":"publisher","first-page":"175628641985498","DOI":"10.1177\/1756286419854986","volume":"12","author":"O Stuve","year":"2019","unstructured":"Stuve O, Soelberg Soerensen P, Leist T, Giovannoni G, Hyvert Y, Damian D, et al. Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers. Ther Adv Neurol Disord. 2019;12:1756286419854986. https:\/\/doi.org\/10.1177\/1756286419854986.","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"1422_CR68","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1073\/pnas.93.4.1716","volume":"93","author":"E Beutler","year":"1996","unstructured":"Beutler E, Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci USA. 1996;93(4):1716\u201320. https:\/\/doi.org\/10.1073\/pnas.93.4.1716.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"1422_CR69","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1046\/j.1525-1381.1999.09115.x","volume":"111","author":"JS Romine","year":"1999","unstructured":"Romine JS, Sipe JC, Koziol JA, Zyroff J, Beutler E. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Physicians. 1999;111(1):35\u201344.","journal-title":"Proc Assoc Am Physicians"},{"issue":"3","key":"1422_CR70","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s40262-018-0693-y","volume":"58","author":"N Terranova","year":"2019","unstructured":"Terranova N, Hicking C, Dangond F, Munafo A. Effects of postponing treatment in the second year of cladribine administration: Clinical trial simulation analysis of absolute lymphocyte counts and relapse rate in patients with relapsing-remitting multiple sclerosis. Clin Pharmacokinet. 2019;58(3):325\u201333. https:\/\/doi.org\/10.1007\/s40262-018-0693-y.","journal-title":"Clin Pharmacokinet"},{"key":"1422_CR71","doi-asserted-by":"publisher","first-page":"175628642093501","DOI":"10.1177\/1756286420935019","volume":"13","author":"PS S\u00f8rensen","year":"2020","unstructured":"S\u00f8rensen PS, Centonze D, Giovannoni G, Montalban X, Selchen D, Vermersch P, et al. Expert opinion on the use of cladribine tablets in clinical practice. Ther Adv Neurol Disord. 2020;13:1756286420935019. https:\/\/doi.org\/10.1177\/1756286420935019.","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"1422_CR72","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40262-018-0695-9","volume":"58","author":"R Hermann","year":"2019","unstructured":"Hermann R, Karlsson MO, Novakovic AM, Terranova N, Fluck M, Munafo A. The clinical pharmacology of cladribine tablets for the treatment of relapsing multiple sclerosis. Clin Pharmacokinet. 2019;58(3):283\u201397. https:\/\/doi.org\/10.1007\/s40262-018-0695-9.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"1422_CR73","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s40262-017-0516-6","volume":"56","author":"RM Savic","year":"2017","unstructured":"Savic RM, Novakovic AM, Ekblom M, Munafo A, Karlsson MO. Population pharmacokinetics of cladribine in patients with multiple sclerosis. Clin Pharmacokinet. 2017;56(10):1245\u201353. https:\/\/doi.org\/10.1007\/s40262-017-0516-6.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"1422_CR74","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s40264-020-00948-x","volume":"43","author":"G Giovannoni","year":"2020","unstructured":"Giovannoni G, Galazka A, Schick R, Leist T, Comi G, Montalban X, et al. Pregnancy outcomes during the clinical development program of cladribine in multiple sclerosis: an integrated analysis of safety. Drug Saf. 2020;43(7):635\u201343. https:\/\/doi.org\/10.1007\/s40264-020-00948-x.","journal-title":"Drug Saf"},{"issue":"4","key":"1422_CR75","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s11481-012-9387-7","volume":"7","author":"V Singh","year":"2012","unstructured":"Singh V, Voss EV, Benardais K, Stangel M. Effects of 2-chlorodeoxyadenosine (Cladribine) on primary rat microglia. J Neuroimmune Pharmacol. 2012;7(4):939\u201350. https:\/\/doi.org\/10.1007\/s11481-012-9387-7.","journal-title":"J Neuroimmune Pharmacol"},{"issue":"5","key":"1422_CR76","first-page":"1235","volume":"54","author":"CM Kearns","year":"1994","unstructured":"Kearns CM, Blakley RL, Santana VM, Crom WR. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. Cancer Res. 1994;54(5):1235\u20139.","journal-title":"Cancer Res"},{"issue":"2","key":"1422_CR77","doi-asserted-by":"publisher","first-page":"120","DOI":"10.2165\/00003088-199732020-00003","volume":"32","author":"J Liliemark","year":"1997","unstructured":"Liliemark J. The clinical pharmacokinetics of cladribine. Clin Pharmacokinet. 1997;32(2):120\u201331. https:\/\/doi.org\/10.2165\/00003088-199732020-00003.","journal-title":"Clin Pharmacokinet"},{"key":"1422_CR78","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.msard.2018.10.006","volume":"27","author":"K Rejdak","year":"2019","unstructured":"Rejdak K, Stelmasiak Z, Grieb P. Cladribine induces long lasting oligoclonal bands disappearance in relapsing multiple sclerosis patients: 10-year observational study. Mult Scler Relat Disord. 2019;27:117\u201320. https:\/\/doi.org\/10.1016\/j.msard.2018.10.006.","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"1422_CR79","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/ana.1032","volume":"50","author":"WI McDonald","year":"2001","unstructured":"McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121\u20137.","journal-title":"Ann Neurol"},{"issue":"3","key":"1422_CR80","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1212\/WNL.53.3.448","volume":"53","author":"F Fazekas","year":"1999","unstructured":"Fazekas F, Barkhof F, Filippi M, Grossman RI, Li DK, McDonald WI, et al. The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. Neurology. 1999;53(3):448\u201356.","journal-title":"Neurology"},{"issue":"1","key":"1422_CR81","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.msard.2011.08.006","volume":"1","author":"K Rammohan","year":"2012","unstructured":"Rammohan K, Giovannoni G, Comi G, Cook S, Rieckmann P, Soelberg Sorensen P, et al. Cladribine tablets for relapsing-remitting multiple sclerosis: efficacy across patient subgroups from the phase III CLARITY study. Mult Scler Relat Disord. 2012;1(1):49\u2013544. https:\/\/doi.org\/10.1016\/j.msard.2011.08.006.","journal-title":"Mult Scler Relat Disord"},{"issue":"Pt 9","key":"1422_CR82","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1093\/brain\/aww173","volume":"139","author":"J Lorscheider","year":"2016","unstructured":"Lorscheider J, Buzzard K, Jokubaitis V, Spelman T, Havrdova E, Horakova D, et al. Defining secondary progressive multiple sclerosis. Brain. 2016;139(Pt 9):2395\u2013405. https:\/\/doi.org\/10.1093\/brain\/aww173.","journal-title":"Brain"},{"issue":"10127","key":"1422_CR83","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","volume":"391","author":"L Kappos","year":"2018","unstructured":"Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(18)30475-6.","journal-title":"Lancet"},{"issue":"5","key":"1422_CR84","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1474-4422(18)30069-3","volume":"17","author":"R Kapoor","year":"2018","unstructured":"Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, et al. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol. 2018;17(5):405\u201315. https:\/\/doi.org\/10.1016\/S1474-4422(18)30069-3.","journal-title":"Lancet Neurol"},{"issue":"3","key":"1422_CR85","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278\u201386. https:\/\/doi.org\/10.1212\/WNL.0000000000000560.","journal-title":"Neurology"},{"key":"1422_CR86","doi-asserted-by":"crossref","unstructured":"Cook S, Rammohan K, Rieckmann P, Soelberg Sorensen P, Vermersch P, Hicking C et al. Slowing of disability progression based on 6-month confirmed EDSS in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets in the CLARITY study: a post-hoc subgroup analysis. American Academy of Neurology (AAN); 15\u201321 April 2016; Vancouver, BC: 1510.","DOI":"10.1212\/WNL.86.16_supplement.P3.058"},{"issue":"4","key":"1422_CR87","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S1474-4422(11)70023-0","volume":"10","author":"G Giovannoni","year":"2011","unstructured":"Giovannoni G, Cook S, Rammohan K, Rieckmann P, Sorensen PS, Vermersch P, et al. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol. 2011;10(4):329\u201337. https:\/\/doi.org\/10.1016\/S1474-4422(11)70023-0.","journal-title":"Lancet Neurol"},{"issue":"6","key":"1422_CR88","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1177\/1352458518771875","volume":"25","author":"G Giovannoni","year":"2019","unstructured":"Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan KW, Rieckmann P, Comi G, et al. Efficacy of cladribine tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: a post hoc analysis of the CLARITY study. Mult Scler. 2019;25(6):819\u201327. https:\/\/doi.org\/10.1177\/1352458518771875.","journal-title":"Mult Scler"},{"issue":"4","key":"1422_CR89","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1007\/s00415-012-6775-0","volume":"260","author":"G Comi","year":"2013","unstructured":"Comi G, Cook SD, Giovannoni G, Rammohan K, Rieckmann P, Sorensen PS, et al. MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. J Neurol. 2013;260(4):1136\u201346. https:\/\/doi.org\/10.1007\/s00415-012-6775-0.","journal-title":"J Neurol"},{"issue":"2","key":"1422_CR90","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1177\/1352458517690269","volume":"24","author":"N De Stefano","year":"2018","unstructured":"De Stefano N, Giorgio A, Battaglini M, De Leucio A, Hicking C, Dangond F, et al. Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. Mult Scler. 2018;24(2):222\u20136. https:\/\/doi.org\/10.1177\/1352458517690269.","journal-title":"Mult Scler"},{"key":"1422_CR91","doi-asserted-by":"publisher","first-page":"175628561775336","DOI":"10.1177\/1756285617753365","volume":"11","author":"G Comi","year":"2018","unstructured":"Comi G, Cook S, Rammohan K, Soelberg Sorensen P, Vermersch P, Adeniji AK, et al. Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study. Ther Adv Neurol Disord. 2018;11:1756285617753365. https:\/\/doi.org\/10.1177\/1756285617753365.","journal-title":"Ther Adv Neurol Disord"},{"issue":"11","key":"1422_CR92","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1212\/WNL.0000000000004313","volume":"89","author":"E Havrdova","year":"2017","unstructured":"Havrdova E, Arnold DL, Cohen JA, Hartung HP, Fox EJ, Giovannoni G, et al. Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy. Neurology. 2017;89(11):1107\u201316. https:\/\/doi.org\/10.1212\/WNL.0000000000004313.","journal-title":"Neurology"},{"key":"1422_CR93","doi-asserted-by":"crossref","unstructured":"Giovannoni G, Keller B, Jack D. Durability of NEDA-3 status in patients with relapsing multiple sclerosis receiving cladribine tablets: CLARITY extension. Berlin, Germany: European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 10\u201312 October 2018. p 894.","DOI":"10.1016\/j.msard.2018.10.090"},{"issue":"3","key":"1422_CR94","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1474-4422(14)70005-5","volume":"13","author":"TP Leist","year":"2014","unstructured":"Leist TP, Comi G, Cree BA, Coyle PK, Freedman MS, Hartung HP, et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol. 2014;13(3):257\u201367. https:\/\/doi.org\/10.1016\/S1474-4422(14)70005-5.","journal-title":"Lancet Neurol"},{"issue":"2","key":"1422_CR95","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald Criteria. Ann Neurol. 2011;69(2):292\u2013302. https:\/\/doi.org\/10.1002\/ana.22366.","journal-title":"Ann Neurol"},{"issue":"6","key":"1422_CR96","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/ana.20703","volume":"58","author":"CH Polman","year":"2005","unstructured":"Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the \"McDonald Criteria\". Ann Neurol. 2005;58(6):840\u20136. https:\/\/doi.org\/10.1002\/ana.20703.","journal-title":"Ann Neurol"},{"issue":"4","key":"1422_CR97","doi-asserted-by":"publisher","first-page":"205521731773280","DOI":"10.1177\/2055217317732802","volume":"3","author":"MS Freedman","year":"2017","unstructured":"Freedman MS, Leist TP, Comi G, Cree BA, Coyle PK, Hartung HP, et al. The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: results from the ORACLE-MS study. Mult Scler J Exp Transl Clin. 2017;3(4):2055217317732802. https:\/\/doi.org\/10.1177\/2055217317732802.","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"2","key":"1422_CR98","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162\u201373. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2.","journal-title":"Lancet Neurol"},{"issue":"3","key":"1422_CR99","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/ene.13853","volume":"26","author":"DH Lee","year":"2019","unstructured":"Lee DH, Peschke M, Utz KS, Linker RA. Diagnostic value of the 2017 McDonald criteria in patients with a first demyelinating event suggestive of relapsing-remitting multiple sclerosis. Eur J Neurol. 2019;26(3):540\u20135. https:\/\/doi.org\/10.1111\/ene.13853.","journal-title":"Eur J Neurol"},{"issue":"5","key":"1422_CR100","doi-asserted-by":"publisher","first-page":"e477","DOI":"10.1212\/NXI.0000000000000477","volume":"5","author":"X Montalban","year":"2018","unstructured":"Montalban X, Leist TP, Cohen BA, Moses H, Campbell J, Hicking C, et al. Cladribine tablets added to IFN-beta in active relapsing MS: the ONWARD study. Neurol Neuroimmunol Neuroinflamm. 2018;5(5):e477. https:\/\/doi.org\/10.1212\/NXI.0000000000000477.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1422_CR101","unstructured":"Miret M WJ, Gedney L, et al, editor. Evaluation of the long-term safety of cladribine tablets in multiple sclerosis design of PREMIERE, a prospective, observational, 8-year safety registry. Berlin, Germany: European Neurological Society (ENS); 19\u201323 June 2010."},{"key":"1422_CR102","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.msard.2018.11.021","volume":"29","author":"S Cook","year":"2019","unstructured":"Cook S, Leist T, Comi G, Montalban X, Giovannoni G, Nolting A, et al. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis. Mult Scler Relat Disord. 2019;29:157\u201367. https:\/\/doi.org\/10.1016\/j.msard.2018.11.021.","journal-title":"Mult Scler Relat Disord"},{"key":"1422_CR103","doi-asserted-by":"crossref","unstructured":"Cook S, Giovannoni G, Leist T, Syed S, Nolting A, Schick R. Updated safety analysis of cladribine tablets in the treatment of patients with multiple sclerosis. Berlin, Germany: European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 10\u201312 October 2018. p 875.","DOI":"10.1016\/j.msard.2018.10.091"},{"issue":"6","key":"1422_CR104","doi-asserted-by":"publisher","first-page":"e158","DOI":"10.1212\/NXI.0000000000000158","volume":"2","author":"J Pakpoor","year":"2015","unstructured":"Pakpoor J, Disanto G, Altmann DR, Pavitt S, Turner BP, Marta M, et al. No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurol Neuroimmunol Neuroinflamm. 2015;2(6):e158. https:\/\/doi.org\/10.1212\/NXI.0000000000000158.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1422_CR105","doi-asserted-by":"crossref","unstructured":"Cook S, Giovannoni G, Leist T, Syed S, Nolting A, Damian D et al. Updated safety analysis of cladribine tablets in the treatment of patients with multiple sclerosis. American Academy of Neurology (AAN); 4\u201310 May 2019; Philadelphia, PA: P2-048.","DOI":"10.1212\/WNL.92.15_supplement.P4.2-046"},{"key":"1422_CR106","unstructured":"European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Long term, prospective, observational cohort study evaluating the safety profile in patients with highly active relapsing multiple sclerosis (RMS) newly started on oral cladribine (CLARION). Registration Number: EUPAS24484. European Medicines Agency. https:\/\/www.encepp.eu\/encepp\/viewResource.htm;jsessionid=RRDIMPSP8OTBkioaK0xjVIqbvMSXLwQLWzCzzwl1SXQsqQBB6TH9!562573046?id=25122. Accessed 15 Jul 2019."},{"key":"1422_CR107","unstructured":"Mavenclad [product information]. Zug: Merck (Schweiz) AG; 2019."},{"key":"1422_CR108","unstructured":"Mavenclad [product monograph]. Mississauga, ON: EMD Serono, Inc.; 2017."},{"key":"1422_CR109","unstructured":"Mavenclad [product information]. Frenchs Forest, NSW: Merck Serono Australia; 2019."},{"issue":"1","key":"1422_CR110","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s13311-015-0409-z","volume":"13","author":"A Shirani","year":"2016","unstructured":"Shirani A, Okuda DT, Stuve O. Therapeutic advances and future prospects in progressive forms of multiple sclerosis. Neurotherapeutics. 2016;13(1):58\u201369. https:\/\/doi.org\/10.1007\/s13311-015-0409-z.","journal-title":"Neurotherapeutics"},{"key":"1422_CR111","unstructured":"PR Newswire. Up to 10-years of follow-up data reaffirm safety profile of investigational cladribine tablets. EMD Serono, Inc. 2018. https:\/\/www.prnewswire.com\/news-releases\/up-to-10-years-of-follow-up-data-reaffirm-safety-profile-of-investigational-cladribine-tablets-873347245.html. Accessed 15 Jul 2019."},{"issue":"8","key":"1422_CR112","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2017.0676","volume":"74","author":"D Baker","year":"2017","unstructured":"Baker D, Herrod SS, Alvarez-Gonzalez C, Giovannoni G, Schmierer K. Interpreting lymphocyte reconstitution data from the pivotal Phase 3 trials of alemtuzumab. JAMA Neurol. 2017;74(8):961\u20139. https:\/\/doi.org\/10.1001\/jamaneurol.2017.0676.","journal-title":"JAMA Neurol"},{"issue":"6","key":"1422_CR113","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1212\/WNL.0b013e318228bec5","volume":"77","author":"M Cossburn","year":"2011","unstructured":"Cossburn M, Pace AA, Jones J, Ali R, Ingram G, Baker K, et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology. 2011;77(6):573\u20139. https:\/\/doi.org\/10.1212\/WNL.0b013e318228bec5.","journal-title":"Neurology"},{"key":"1422_CR114","unstructured":"Glatopa [package insert]. Princeton, NJ: Sandoz Inc.; 2018."},{"issue":"1\u20132","key":"1422_CR115","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jneuroim.2014.08.622","volume":"276","author":"RZ Hussain","year":"2014","unstructured":"Hussain RZ, Hayardeny L, Cravens PC, Yarovinsky F, Eagar TN, Arellano B, et al. Immune surveillance of the central nervous system in multiple sclerosis\u2013relevance for therapy and experimental models. J Neuroimmunol. 2014;276(1\u20132):9\u201317. https:\/\/doi.org\/10.1016\/j.jneuroim.2014.08.622.","journal-title":"J Neuroimmunol"},{"key":"1422_CR116","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/DNND.S161450","volume":"8","author":"AN Boyko","year":"2018","unstructured":"Boyko AN, Boyko OV. Cladribine tablets' potential role as a key example of selective immune reconstitution therapy in multiple sclerosis. Degener Neurol Neuromuscul Dis. 2018;8:35\u201344. https:\/\/doi.org\/10.2147\/DNND.S161450.","journal-title":"Degener Neurol Neuromuscul Dis"},{"key":"1422_CR117","doi-asserted-by":"crossref","unstructured":"Nicholas J, Edwards NC, Edwards RA, Dellarole A, Manca L, Harlow DE et al. Predictors of non-adherence among patients with multiple sclerosis newly initiating once- or twice-daily oral disease-modifying drugs. International Society for Pharmacoeconomics and Outcomes Research (ISPOR); 18\u201322 May 2019; New Orleans, LA: PND91.","DOI":"10.1016\/j.jval.2019.04.1364"},{"issue":"2","key":"1422_CR118","doi-asserted-by":"publisher","first-page":"240","DOI":"10.2337\/dc09-1348","volume":"33","author":"M Peyrot","year":"2010","unstructured":"Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care. 2010;33(2):240\u20135. https:\/\/doi.org\/10.2337\/dc09-1348.","journal-title":"Diabetes Care"},{"key":"1422_CR119","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2147\/PPA.S115090","volume":"11","author":"M Tintore","year":"2017","unstructured":"Tintore M, Alexander M, Costello K, Duddy M, Jones DE, Law N, et al. The state of multiple sclerosis: current insight into the patient\/health care provider relationship, treatment challenges, and satisfaction. Patient Prefer Adherence. 2017;11:33\u201345. https:\/\/doi.org\/10.2147\/PPA.S115090.","journal-title":"Patient Prefer Adherence"},{"key":"1422_CR120","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.2147\/PPA.S67334","volume":"8","author":"A Crawford","year":"2014","unstructured":"Crawford A, Jewell S, Mara H, McCatty L, Pelfrey R. Managing treatment fatigue in patients with multiple sclerosis on long-term therapy: the role of multiple sclerosis nurses. Patient Prefer Adherence. 2014;8:1093\u20139. https:\/\/doi.org\/10.2147\/PPA.S67334.","journal-title":"Patient Prefer Adherence"},{"issue":"1 Suppl A","key":"1422_CR121","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.18553\/jmcp.2013.19.s1.S24","volume":"19","author":"J Menzin","year":"2013","unstructured":"Menzin J, Caon C, Nichols C, White LA, Friedman M, Pill MW. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. J Manag Care Pharm. 2013;19(1 Suppl A):S24\u2013S40. https:\/\/doi.org\/10.18553\/jmcp.2013.19.s1.S24.","journal-title":"J Manag Care Pharm"},{"issue":"7","key":"1422_CR122","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1021\/jm00277a010","volume":"15","author":"LF Christensen","year":"1972","unstructured":"Christensen LF, Broom AD, Robins MJ, Bloch A. Synthesis and biological activity of selected 2,6-disubstituted-(2-deoxy-\u03b1-and-\u03b2-d-erythro-pentofuranosyl)purines. J Med Chem. 1972;15(7):735\u20139. https:\/\/doi.org\/10.1021\/jm00277a010.","journal-title":"J Med Chem"},{"key":"1422_CR123","unstructured":"EMD Serono, Inc. Prospective observational long-term safety registry of multiple sclerosis patients who have participated in cladribine clinical trials (PREMIERE). ClinicalTrials.gov. 2018. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01013350. Accessed 15 Jul 2019."},{"key":"1422_CR124","unstructured":"US Food and Drug Administration. FDA Approved Drug Products\u2014Leustatin. 1993. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=020229. Accessed 15 Jul 2019."},{"key":"1422_CR125","unstructured":"MS Research Australia. Relapsing MS treatment cladribine on the comeback. 2017. https:\/\/msra.org.au\/news\/relapsing-ms-treatment-cladribine-comeback\/. Accessed 15 Jul 2019."},{"key":"1422_CR126","unstructured":"Merck Serono Europe Limited withdraws its marketing authorisation application for Movectro (cladribine) [press release]. European Medicines Agency; 11 February 2011. https:\/\/www.ema.europa.eu\/en\/documents\/press-release\/merck-serono-europe-limited-withdraws-its-marketing-authorisation-application-movectro-cladribine_en.pdf. Accessed 11 Feb 2020."},{"key":"1422_CR127","unstructured":"FDA grants priority review to cladribine tablets for the treatment of relapsing forms of MS [press release]. EMD Serono, Inc.; 28 July 2010. https:\/\/media.emdserono.com\/2010-07-28-EMD-SERONO-INC-FDA-GRANTS-PRIORITY-REVIEW-TO-CLADRIBINE-TABLETS-FOR-THE-TREATMENT-OF-RELAPSING-FORMS-OF-MS. Accessed 15 Jul 2019."},{"key":"1422_CR128","unstructured":"PR Newswire. EMD Serono receives complete response letter from FDA on cladribine tablets new drug application. 2011. https:\/\/www.prnewswire.com\/news-releases\/emd-serono-receives-complete-response-letter-from-fda-on-cladribine-tablets-new-drug-application-117220383.html. Accessed 15 Jul 2019."},{"key":"1422_CR129","unstructured":"The Pharma Letter. EMA accepts Merck\u2019s MAA for cladribine tablets in multiple sclerosis. 2016. https:\/\/www.thepharmaletter.com\/article\/ema-accepts-merck-s-maa-for-cladribine-tablet-in-multiple-sclerosis. Accessed 15 Jul 2019."},{"key":"1422_CR130","unstructured":"European Commission grants approval for mavenclad (cladribine tablets) [press release]. Merck KGaA; 25 August 2017. https:\/\/www.emdgroup.com\/en\/news\/mavenclad-25-08-2017.html. Accessed 15 Jul 2019."},{"key":"1422_CR131","unstructured":"FDA accepts file for cladribine tablets as potential treatment for relapsing forms of multiple sclerosis [press release]. EMD Serono, Inc.; 30 July 2018. https:\/\/media.emdserono.com\/FDA-Accepts-File-for-Cladribine-Tablets. Accessed 11 Feb 2020."},{"key":"1422_CR132","doi-asserted-by":"crossref","unstructured":"Soelberg-Sorensen P, Dangond F, Hicking C, Giovannoni G. Long-term lymphocyte counts in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets 3.5 mg\/kg: total lymphocytes, b and t cell subsets. Paris, France: European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 25\u201328 October 2017.","DOI":"10.26226\/morressier.59a3eda8d462b8028d8950f6"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01422-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-020-01422-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01422-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,18]],"date-time":"2024-08-18T06:17:55Z","timestamp":1723961875000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-020-01422-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,28]]},"references-count":132,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1422"],"URL":"https:\/\/doi.org\/10.1007\/s40265-020-01422-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,28]]},"assertion":[{"value":"28 November 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Funding for writing and editorial support was provided by EMD Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Kottil Rammohan received honoraria for lectures and steering committee meetings from EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, Biogen, Sanofi-Aventis, Genzyme, Novartis, Teva Neurosciences, Acorda, and Roche\/Genentech. Patricia K. Coyle received consultancy fees from Accordant, Actelion, Alexion, Bayer, Biogen, Celgene, Genentech\/Roche, Novartis, Sanofi Genzyme, EMD Serono, Inc., an affiliate of Merk KGaA, Darmstadt, Germany, and TG Therapeutics, and also received research grants from Actelion Pharmaceuticals, Inc., Alkermes, Genentech\/Roche, MedDay Pharmaceuticals, NINDS, and Novartis Pharmaceuticals. Elke Sylvester is an employee of Merck KGaA, Darmstadt, Germany. Andrew Galazka is an employee of Ares Trading SA, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany. Fernando Dangond is an employee of EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany. Megan Grosso is an employee of EMD Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany. Thomas P. Leist received consultancy fees or clinical research grants from Alkermes, Bayer, Biogen, EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, Genentech, Genzyme, and Novartis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the drafting of the manuscript and revising it critically for important intellectual content.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}